|
gptkbp:instance_of
|
gptkb:chemical_compound
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Atropine
|
|
gptkbp:activities
|
anticholinergic
|
|
gptkbp:approves
|
1950s
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:brand
|
gptkb:Atropen
gptkb:Isopto_Atropine
Sal-Tropine
|
|
gptkbp:class
|
gptkb:drug
|
|
gptkbp:clinical_trial
|
Phase IV
Phase II
Phase III
Phase I
|
|
gptkbp:contraindication
|
gptkb:sneaker
gptkb:Insurance_Company
prostatic hypertrophy
|
|
gptkbp:developed_by
|
gptkb:Atropa_belladonna
|
|
gptkbp:discovered_by
|
gptkb:Sir_Robert_Christison
|
|
gptkbp:dissolved
|
soluble in water
soluble in alcohol
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Atropine sulfate
|
|
gptkbp:ingredients
|
C17 H23 N O3 S
|
|
gptkbp:is_atype_of
|
A03 B A01
|
|
gptkbp:is_used_for
|
organophosphate poisoning
bradycardia
pre-anesthesia
|
|
gptkbp:legal_issue
|
Rx-only
|
|
gptkbp:level
|
9.7
4.5 to 6.5
|
|
gptkbp:manager
|
intravenous
subcutaneous
intramuscular
|
|
gptkbp:mass
|
345.44 g/mol
|
|
gptkbp:monitors
|
0 A8 S0 D1 R8 A
|
|
gptkbp:related_to
|
gptkb:scopolamine
hyoscyamine
belladonna alkaloids
|
|
gptkbp:side_effect
|
constipation
dry mouth
blurred vision
increases heart rate
tachycardia
urinary retention
decreases secretions
dilates pupils
relaxes smooth muscles
|
|
gptkbp:storage
|
room temperature
protected from light
|
|
gptkbp:type_of
|
51-55-8
|